Zoledronic acid is a potent, new-generation bisphosphonate indicated for the treatment of documented bone metastasis in patients with solid tumors and bone lesions associated with multiple myeloma.

the most common sites of metastasis were: bone (in 54.06% of those with metastatic cancer) lung (in 14.18%) liver (in 10.5%) brain (in 1.6%) Additionally, 19.67% of people had metastasis in ...

Patients mainly experience bone metastasis, which develops when the cancer cells migrate to the bone from another affected ...

Raman is also a member of the Johns Hopkins Kimmel Cancer Center. “We first had to determine whether DDX3 was expressed in ...

Their findings hold promise for advancing the development of preclinical tools to predict breast cancer bone metastasis. Researchers from Tampere University, Finland, and Izmir Institute of ...

Their findings hold promise for advancing the development of preclinical tools to predict breast cancer bone metastasis. Breast cancer is a significant global public health challenge, with 2.3 ...

Median overall survival (OS) increased from 19.3 months with upfront immune checkpoint inhibition (ICI) to 41.3 months when a ...

The average time from consultation to treatment for bone metastases decreased by almost 4 days with virtual simulation ...

In a new study led by Johns Hopkins Medicine, the drug RK-33 has demonstrated promise in treating breast cancer that has spread to the bone (breast cancer bone metastasis). RK-33 was previously ...

Zoledronic acid reduces the incidence of skeletal-related events (SREs) in bone metastatic CRPC (mCRPC). Denosumab compared with zoledronic acid improves the median time to the first skeletal ...

In a new study led by Johns Hopkins Medicine, the drug RK-33 has demonstrated promise in treating breast cancer that has spread to the bone (breast cancer bone metastasis).RK-33 was previously ...